Ireland
--:--IST
Latest
Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity
Priya Life Science Rare disease register
All regulatorsEMA approvalsEU safety letters
European Union · EMA · Rare diseases

EU orphan designations

Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.

Source: European Medicines Agency, orphan designations data (reproduced with acknowledgement of the source). Synced 12 Oct 2026
3,310Orphan designations listed
2,204Currently active
125Designated in the last 12 months
1,070Withdrawn or expired
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from EMA orphan designation records · Last verified · Editorial standards
01

Matching designations

3 matches
SubstanceIntended useStatusDesignated
acalabrutinib
EU/3/16/1626
48 clinical trials →		 Treatment of lymphoplasmacytic lymphoma Active (positive) 21 Mar 2016
acalabrutinib
EU/3/16/1625
48 clinical trials →		 Treatment of mantle cell lymphoma Withdrawn 21 Mar 2016
acalabrutinib
EU/3/16/1624
48 clinical trials →		 Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma Withdrawn 21 Mar 2016

New orphan designations and approvals, weekly

One email every Friday: new EMA, FDA and Health Canada approvals, EU and US medicine shortages, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.

A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 12 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.